Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prime-2-CoV_Beta Orf virus-based COVID-19 booster dose-finding study
2024-511266-36-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of PRIME-2-CoV_Beta in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Tübingen. Planned start Mar 2024; status: authorised.
02
Drugs
PRIME-2-CoV_Beta
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-511266-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511266-36-00.